Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 20:19 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4Not yet recruitingINTERVENTIONAL

Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone

ClinicalTrials.gov · NCT06865365 · Registry updated: 2025-03-21

Condition / research focus: Obesity, Adolescent
Sponsor: Medical University of Vienna
Countries with listed sites: No country reported
Registry dates and results: Start: 2025-05-01. Completion: 2028-02-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions (drug)
Dietologic measures and lifestyle optimization for weight loss (behavioral)

Where the study takes place — 0 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

ClinicalTrials.gov · NCT03158805 · Registry updated: 2025-03-12

Condition / research focus: Bipolar Disorder; Obesity
Sponsor: Lindner Center of HOPE
Countries with listed sites: United States
Registry dates and results: Start: 2017-04-26. Completion: 2023-01-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LIRAGLUTIDE (drug) — also listed as: Saxenda
Placebo (other)

Where the study takes place — 1 listed sites

Lindner Center of HOPE
Mason, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Liraglutide and Peripheral Artery Disease

ClinicalTrials.gov · NCT04881110 · Registry updated: 2025-03-03

Condition / research focus: Type 2 Diabetes; Peripheral Arterial Disease
Sponsor: University of Campania Luigi Vanvitelli
Countries with listed sites: Italy
Registry dates and results: Start: 2021-02-01. Completion: 2022-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Intervention group
Control (other) — also listed as: Control group

Where the study takes place — 1 listed sites

Unit of Endocrinology and Metabolic Diseases and Unit of Diabetes, University of Campania Luigi Vanvitelli
Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study That Tests AD109 in Patients Taking GLP-1 Drugs

ClinicalTrials.gov · NCT06400615 · Registry updated: 2025-02-19

Condition / research focus: OSA
Sponsor: Apnimed
Countries with listed sites: United States
Registry dates and results: Start: 2024-05-20. Completion: 2024-12-26 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AD109 (drug)

Where the study takes place — 4 listed sites

Pinnacle Research Group, LLC
Anniston, Alabama, United States
Site recruitment: Not reported
Clinical Neuroscience Solutions, Inc
Jacksonville, Florida, United States
Site recruitment: Not reported
Monroe Biomedical Research
Monroe, North Carolina, United States
Site recruitment: Not reported
Clinical Neuroscience Solutions, Inc
Memphis, Tennessee, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4WithdrawnINTERVENTIONAL

Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity

ClinicalTrials.gov · NCT05812183 · Registry updated: 2025-02-14

Condition / research focus: Dyspnea; Quality of Life
Sponsor: University of California, Los Angeles
Countries with listed sites: No country reported
Registry dates and results: Start: 2023-07-09. Completion: 2025-02-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bariatric surgery (device)
Medical weight loss (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

ClinicalTrials.gov · NCT06818292 · Registry updated: 2025-02-10

Condition / research focus: Healthy
Sponsor: Nils Opel
Countries with listed sites: Germany
Registry dates and results: Start: 2024-10-21. Completion: 2024-12-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (biological) — also listed as: GLP-1 Agonist
Placebo (biological)

Where the study takes place — 1 listed sites

Department of Psychiatry and Psychotherapy, University Hospital Jena
Jena, Thuringia, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2RecruitingINTERVENTIONAL

Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT05268237 · Registry updated: 2025-02-06

Condition / research focus: Diabete Type 2
Sponsor: Biolingus
Countries with listed sites: Hong Kong
Registry dates and results: Start: 2023-04-25. Completion: 2026-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Clinical Trials Unit, Chinese University of Hong Kong
Hong Kong, Hong Kong
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effects of Liraglutide on Body Surface Gastric Mapping

ClinicalTrials.gov · NCT06500130 · Registry updated: 2025-01-29

Condition / research focus: Gastroparesis; Functional Dyspepsia; Chronic Nausea and Vomiting Syndrome; Healthy
Sponsor: Alimetry
Countries with listed sites: New Zealand
Registry dates and results: Start: 2024-05-30. Completion: 2024-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Body Surface Gastric Mapping (device)

Where the study takes place — 1 listed sites

Alimetry Clinic
Auckland, Auckland, New Zealand
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

ClinicalTrials.gov · NCT03087032 · Registry updated: 2025-01-13

Condition / research focus: Type 2 Diabetes Patients; Overweight and Obesity; Hyperglycaemia (Diabetic)
Sponsor: The First Affiliated Hospital of Xiamen University
Countries with listed sites: China
Registry dates and results: Start: 2019-01-10. Completion: 2025-02-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victozaa, Liraglutid, Liroglutide, Liraglutidum, Liraglutide Acetate
insulin glargine (drug) — also listed as: Lantus

Where the study takes place — 1 listed sites

The first afilliated hospital of Xiamen university
Xiamen, Fujian, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

ClinicalTrials.gov · NCT05794581 · Registry updated: 2024-12-27

Condition / research focus: Type 1 Diabetes
Sponsor: Carmot Therapeutics, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2023-03-21. Completion: 2024-04-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CT-868 (drug)
Placebo (drug)
Victoza (drug) — also listed as: Liraglutide

Where the study takes place — 1 listed sites

Carmot Clinical Research Unit 101
Chula Vista, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

ClinicalTrials.gov · NCT06361238 · Registry updated: 2024-12-20

Condition / research focus: Delirium, Postoperative
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Countries with listed sites: China
Registry dates and results: Start: 2024-11-19. Completion: 2028-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide injection (drug) — also listed as: Victoza
Placebo injection (drug) — also listed as: Normal saline

Where the study takes place — 1 listed sites

Wenxue liu
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity

ClinicalTrials.gov · NCT06720246 · Registry updated: 2024-12-11

Condition / research focus: Obesity and Overweight
Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Countries with listed sites: Italy
Registry dates and results: Start: 2024-06-26. Completion: 2027-05-01 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

IRCCS Ospedale Galeazzi-Sant'Ambrogio
Milan, Milan, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

ClinicalTrials.gov · NCT04883346 · Registry updated: 2024-11-20

Condition / research focus: Obesity; Status Post Sleeve Gastrectomy
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Countries with listed sites: United States
Registry dates and results: Start: 2021-06-21. Completion: 2024-04-30 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Saxenda

Where the study takes place — 1 listed sites

National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Comprehensive Clinical Evaluation Study of GLP-1RA

ClinicalTrials.gov · NCT06686134 · Registry updated: 2024-11-13

Condition / research focus: T2DM
Sponsor: LI YAN
Countries with listed sites: China
Registry dates and results: Start: 2024-07-01. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Yan Li
Jinan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

ClinicalTrials.gov · NCT03555994 · Registry updated: 2024-11-12

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: MedImmune LLC
Countries with listed sites: Netherlands · Sweden · United Kingdom
Registry dates and results: Start: 2018-05-31. Completion: 2021-04-14 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

MEDI0382 (drug)
Placebo (drug)
Liraglutide (drug)

Where the study takes place — 3 listed sites

Research Site
Maastricht, Netherlands
Site recruitment: Not reported
Research Site
Uppsala, Sweden
Site recruitment: Not reported
Research Site
Nottingham, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableEnrolling by invitationOBSERVATIONAL

GLP_1 RA Ultrasound Study

ClinicalTrials.gov · NCT06581120 · Registry updated: 2024-11-07

Condition / research focus: Glucagon Like Peptide-1 (GLP-1; Delayed Gastric Emptying; Risk of Aspiration; Diabetes; Morbid Obesity
Sponsor: Children's Hospital Medical Center, Cincinnati
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-08. Completion: 2026-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-Like Peptide-1 receptor agonists (drug)
Point of Care Gastric Ultrasound (diagnostic_test) — also listed as: POGUS

Where the study takes place — 1 listed sites

Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

ClinicalTrials.gov · NCT04199728 · Registry updated: 2024-11-06

Condition / research focus: Opiate Substitution Treatment; Opioid-Related Disorders
Sponsor: Milton S. Hershey Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2021-10-18. Completion: 2023-09-13 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Pen Injector (drug) — also listed as: Saxenda
Placebo (drug)

Where the study takes place — 1 listed sites

Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

ClinicalTrials.gov · NCT03115424 · Registry updated: 2024-09-27

Condition / research focus: Obesity
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2017-06-22. Completion: 2024-05-30 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda (drug) — also listed as: Liraglutide
Placebos (drug) — also listed as: Placebo for Saxenda (Liraglutide)
RYGB (procedure)

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3WithdrawnINTERVENTIONAL

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

ClinicalTrials.gov · NCT04683237 · Registry updated: 2024-09-26

Condition / research focus: Atypical Endometrial Hyperplasia; Obese; Fertility Issues
Sponsor: Xiaojun Chen
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-03-20. Completion: 2026-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Injection (drug) — also listed as: victoza, Nuo he li
Megestrol Acetate 160 MG (drug) — also listed as: Yi li zhi, Megace

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

ClinicalTrials.gov · NCT04531176 · Registry updated: 2024-09-19

Condition / research focus: Type 2 Diabetes; Obesity
Sponsor: The Cleveland Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-01. Completion: 2023-08-04 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Weight Management Program (WMP) (other)
Traditional care (other)
Phentermine / Topiramate Extended Release Oral Capsule (drug)
naltrexone/bupropion extended-release (drug)
liraglutide 3.0 mg (drug)
Orlistat (drug)

Where the study takes place — 1 listed sites

Cleveland Clinic
Cleveland, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 20:19 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4Not yet recruitingINTERVENTIONAL

Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone

ClinicalTrials.gov · NCT06865365 · Registry updated: 2025-03-21

Condition / research focus: Obesity, Adolescent
Sponsor: Medical University of Vienna
Countries with listed sites: No country reported
Registry dates and results: Start: 2025-05-01. Completion: 2028-02-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions (drug)
Dietologic measures and lifestyle optimization for weight loss (behavioral)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

ClinicalTrials.gov · NCT03158805 · Registry updated: 2025-03-12

Condition / research focus: Bipolar Disorder; Obesity
Sponsor: Lindner Center of HOPE
Countries with listed sites: United States
Registry dates and results: Start: 2017-04-26. Completion: 2023-01-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LIRAGLUTIDE (drug) — also listed as: Saxenda
Placebo (other)

Where the study takes place — 1 listed sites

Lindner Center of HOPE
Mason, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Liraglutide and Peripheral Artery Disease

ClinicalTrials.gov · NCT04881110 · Registry updated: 2025-03-03

Condition / research focus: Type 2 Diabetes; Peripheral Arterial Disease
Sponsor: University of Campania Luigi Vanvitelli
Countries with listed sites: Italy
Registry dates and results: Start: 2021-02-01. Completion: 2022-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Intervention group
Control (other) — also listed as: Control group

Where the study takes place — 1 listed sites

Unit of Endocrinology and Metabolic Diseases and Unit of Diabetes, University of Campania Luigi Vanvitelli
Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study That Tests AD109 in Patients Taking GLP-1 Drugs

ClinicalTrials.gov · NCT06400615 · Registry updated: 2025-02-19

Condition / research focus: OSA
Sponsor: Apnimed
Countries with listed sites: United States
Registry dates and results: Start: 2024-05-20. Completion: 2024-12-26 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AD109 (drug)

Where the study takes place — 4 listed sites

Pinnacle Research Group, LLC
Anniston, Alabama, United States
Site recruitment: Not reported
Clinical Neuroscience Solutions, Inc
Jacksonville, Florida, United States
Site recruitment: Not reported
Monroe Biomedical Research
Monroe, North Carolina, United States
Site recruitment: Not reported
Clinical Neuroscience Solutions, Inc
Memphis, Tennessee, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4WithdrawnINTERVENTIONAL

Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity

ClinicalTrials.gov · NCT05812183 · Registry updated: 2025-02-14

Condition / research focus: Dyspnea; Quality of Life
Sponsor: University of California, Los Angeles
Countries with listed sites: No country reported
Registry dates and results: Start: 2023-07-09. Completion: 2025-02-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bariatric surgery (device)
Medical weight loss (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

ClinicalTrials.gov · NCT06818292 · Registry updated: 2025-02-10

Condition / research focus: Healthy
Sponsor: Nils Opel
Countries with listed sites: Germany
Registry dates and results: Start: 2024-10-21. Completion: 2024-12-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (biological) — also listed as: GLP-1 Agonist
Placebo (biological)

Where the study takes place — 1 listed sites

Department of Psychiatry and Psychotherapy, University Hospital Jena
Jena, Thuringia, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2RecruitingINTERVENTIONAL

Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT05268237 · Registry updated: 2025-02-06

Condition / research focus: Diabete Type 2
Sponsor: Biolingus
Countries with listed sites: Hong Kong
Registry dates and results: Start: 2023-04-25. Completion: 2026-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Clinical Trials Unit, Chinese University of Hong Kong
Hong Kong, Hong Kong
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effects of Liraglutide on Body Surface Gastric Mapping

ClinicalTrials.gov · NCT06500130 · Registry updated: 2025-01-29

Condition / research focus: Gastroparesis; Functional Dyspepsia; Chronic Nausea and Vomiting Syndrome; Healthy
Sponsor: Alimetry
Countries with listed sites: New Zealand
Registry dates and results: Start: 2024-05-30. Completion: 2024-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Body Surface Gastric Mapping (device)

Where the study takes place — 1 listed sites

Alimetry Clinic
Auckland, Auckland, New Zealand
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

ClinicalTrials.gov · NCT03087032 · Registry updated: 2025-01-13

Condition / research focus: Type 2 Diabetes Patients; Overweight and Obesity; Hyperglycaemia (Diabetic)
Sponsor: The First Affiliated Hospital of Xiamen University
Countries with listed sites: China
Registry dates and results: Start: 2019-01-10. Completion: 2025-02-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victozaa, Liraglutid, Liroglutide, Liraglutidum, Liraglutide Acetate
insulin glargine (drug) — also listed as: Lantus

Where the study takes place — 1 listed sites

The first afilliated hospital of Xiamen university
Xiamen, Fujian, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

ClinicalTrials.gov · NCT05794581 · Registry updated: 2024-12-27

Condition / research focus: Type 1 Diabetes
Sponsor: Carmot Therapeutics, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2023-03-21. Completion: 2024-04-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CT-868 (drug)
Placebo (drug)
Victoza (drug) — also listed as: Liraglutide

Where the study takes place — 1 listed sites

Carmot Clinical Research Unit 101
Chula Vista, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

ClinicalTrials.gov · NCT06361238 · Registry updated: 2024-12-20

Condition / research focus: Delirium, Postoperative
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Countries with listed sites: China
Registry dates and results: Start: 2024-11-19. Completion: 2028-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide injection (drug) — also listed as: Victoza
Placebo injection (drug) — also listed as: Normal saline

Where the study takes place — 1 listed sites

Wenxue liu
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity

ClinicalTrials.gov · NCT06720246 · Registry updated: 2024-12-11

Condition / research focus: Obesity and Overweight
Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Countries with listed sites: Italy
Registry dates and results: Start: 2024-06-26. Completion: 2027-05-01 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

IRCCS Ospedale Galeazzi-Sant'Ambrogio
Milan, Milan, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

ClinicalTrials.gov · NCT04883346 · Registry updated: 2024-11-20

Condition / research focus: Obesity; Status Post Sleeve Gastrectomy
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Countries with listed sites: United States
Registry dates and results: Start: 2021-06-21. Completion: 2024-04-30 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Saxenda

Where the study takes place — 1 listed sites

National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Comprehensive Clinical Evaluation Study of GLP-1RA

ClinicalTrials.gov · NCT06686134 · Registry updated: 2024-11-13

Condition / research focus: T2DM
Sponsor: LI YAN
Countries with listed sites: China
Registry dates and results: Start: 2024-07-01. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Yan Li
Jinan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

ClinicalTrials.gov · NCT03555994 · Registry updated: 2024-11-12

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: MedImmune LLC
Countries with listed sites: Netherlands · Sweden · United Kingdom
Registry dates and results: Start: 2018-05-31. Completion: 2021-04-14 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

MEDI0382 (drug)
Placebo (drug)
Liraglutide (drug)

Where the study takes place — 3 listed sites

Research Site
Maastricht, Netherlands
Site recruitment: Not reported
Research Site
Uppsala, Sweden
Site recruitment: Not reported
Research Site
Nottingham, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableEnrolling by invitationOBSERVATIONAL

GLP_1 RA Ultrasound Study

ClinicalTrials.gov · NCT06581120 · Registry updated: 2024-11-07

Condition / research focus: Glucagon Like Peptide-1 (GLP-1; Delayed Gastric Emptying; Risk of Aspiration; Diabetes; Morbid Obesity
Sponsor: Children's Hospital Medical Center, Cincinnati
Countries with listed sites: United States
Registry dates and results: Start: 2024-07-08. Completion: 2026-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-Like Peptide-1 receptor agonists (drug)
Point of Care Gastric Ultrasound (diagnostic_test) — also listed as: POGUS

Where the study takes place — 1 listed sites

Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

ClinicalTrials.gov · NCT04199728 · Registry updated: 2024-11-06

Condition / research focus: Opiate Substitution Treatment; Opioid-Related Disorders
Sponsor: Milton S. Hershey Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2021-10-18. Completion: 2023-09-13 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Pen Injector (drug) — also listed as: Saxenda
Placebo (drug)

Where the study takes place — 1 listed sites

Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

ClinicalTrials.gov · NCT03115424 · Registry updated: 2024-09-27

Condition / research focus: Obesity
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2017-06-22. Completion: 2024-05-30 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda (drug) — also listed as: Liraglutide
Placebos (drug) — also listed as: Placebo for Saxenda (Liraglutide)
RYGB (procedure)

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3WithdrawnINTERVENTIONAL

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

ClinicalTrials.gov · NCT04683237 · Registry updated: 2024-09-26

Condition / research focus: Atypical Endometrial Hyperplasia; Obese; Fertility Issues
Sponsor: Xiaojun Chen
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-03-20. Completion: 2026-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Injection (drug) — also listed as: victoza, Nuo he li
Megestrol Acetate 160 MG (drug) — also listed as: Yi li zhi, Megace

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

ClinicalTrials.gov · NCT04531176 · Registry updated: 2024-09-19

Condition / research focus: Type 2 Diabetes; Obesity
Sponsor: The Cleveland Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-01. Completion: 2023-08-04 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Weight Management Program (WMP) (other)
Traditional care (other)
Phentermine / Topiramate Extended Release Oral Capsule (drug)
naltrexone/bupropion extended-release (drug)
liraglutide 3.0 mg (drug)
Orlistat (drug)

Where the study takes place — 1 listed sites

Cleveland Clinic
Cleveland, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →